InsidersTradesSigma
Total declarations
Company
▲ Purchases (1 ops.)
▼ Sales (3 ops.)
Insider track record
ExecutiveDisclosed buys
1
Disclosed sells
3
T+90 hit rate
44%
T+90 mean return
+15.3%
Across 9 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the full record of transactions filed by Longpre Lara, Directeur du Développement. Director active across 1 company, notably Mirum Pharmaceuticals, Inc.. Cumulatively, 17 disclosures have been recorded. Breakdown: 1 buy · 3 sells. Total volume traded: €79k. History available since 10 May 2021. The latest transaction was filed on 10 September 2019 (Acquisition). Regulator: SEC (Form 4). All data is openly available.
Declarations17 total
965 shares@ US$10.645.6% of flowCommon StockSEC:0001415889-24-008316:0
Ideal exit: 6 Jun 2020 (T+270)
847 shares@ US$26.191812.2% of flowCommon StockSEC:0001415889-24-002756:0
1,019 shares@ US$28.03515.6% of flowCommon StockSEC:0001415889-24-000883:0
434 shares@ US$22.2875.4% of flowCommon StockSEC:0001209191-23-055434:0
1,004 shares@ US$25.646614.1% of flowCommon StockSEC:0001209191-23-041338:0
684 shares@ US$16.92356.3% of flowCommon StockSEC:0001209191-23-030966:0
9,625 shares0Common StockSEC:0001209191-23-006312:0
82 shares@ US$17.0510.8% of flowCommon StockSEC:0001209191-22-056887:0
1,454 shares@ US$13.5660.0005% mcap28.1% of flowCommon StockSEC:0001209191-22-028726:0
10,000 shares0Common StockSEC:0001209191-22-002428
10,000 shares0Common StockSEC:0001209191-22-002428:0
753 shares@ US$13.5150.0002% mcap13.2% of flowCommon StockSEC:0001209191-21-064449:0
753 shares@ US$13.5150.0002% mcap36.7% of flowCommon StockSEC:0001209191-21-064449
8,125 shares0Common StockSEC:0001209191-21-058606:0
8,125 shares0Common StockSEC:0001209191-21-058606
1,259 shares@ US$14.6222.8% of flowCommon StockSEC:0001209191-21-032154
1,259 shares@ US$14.620.0004% mcap22.8% of flowCommon StockSEC:0001209191-21-032154:0
17 of 17 declarations
About Longpre Lara
Lara Longpre is the Chief Development Officer at Mirum Pharmaceuticals, Inc. She is responsible for business development strategy and expanding the company's operations. Her expertise in the pharmaceutical sector is a major asset for the organization's growth.
